SSGJ-705 Monotherapy and Combination Therapy in Advanced HER2-Expressing Solid Tumors

NCT07022002 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

340

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced, Recurrent or Metastatic Malignancies

Interventions

DRUG: SSGJ-705
DRUG: PD-1/L1 inhibitor combined with chemotherapy
DRUG: SSGJ-705 combined with chemotherapy

Sponsor

Shenyang Sunshine Pharmaceutical Co., LTD.